Clinical Trial Update: Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating conversion therapy for gastric cancer using the PD-1 inhibitor Adebrelimab plus Apatinib in combination with the SOX chemother…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Gastric Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• Apatinib (apatinib)

Snippet

Sponsor: Beijing Friendship Hospital | Conditions: Adebrelimab, Adenocarcinoma of GE Junction | Phase 2 | Status: RECRUITING